Wondering when will retatrutide be available? Here's the latest retatrutide release date outlook, approval timeline, and global availability by country.
Retatrutide is not available yet. It is still in Phase 3 clinical trials, no regulatory agency has approved it, and outside of a trial there is no legal way to obtain it anywhere in the world. Based on Lilly's program milestones and how long other GLP-1 drugs take to move from late-stage data to pharmacy shelves, a US approval decision in 2027 or later is the most realistic expectation.
Retatrutide availability today: trial access only
Retatrutide (LY3437943) is an investigational triple receptor agonist that targets GLP-1, GIP, and glucagon receptors at the same time. Eli Lilly is running it through the Phase 3 TRIUMPH program, which includes several large trials in obesity, type 2 diabetes, obstructive sleep apnea, and related conditions.
Phase 3 status means the drug has cleared early safety and dosing hurdles, but it does not mean retatrutide is close to pharmacy shelves. Nothing about retatrutide is approved yet, and the only legitimate access point is enrollment in one of those trials.
- No FDA approval in the United States
- No EMA authorization in the European Union
- No MHRA or Health Canada approval
- No prescription, pharmacy, or telehealth supply in any country
Retatrutide is not approved for human use by any regulatory agency, so any website selling it is selling something that has not been reviewed for safety, purity, or potency.
Retatrutide release date: a realistic timeline
Lilly has not published a firm retatrutide release date. The estimates below are projections based on program milestones and the typical path from Phase 3 readouts to a commercial launch.
| Milestone | Expected window | Status |
|---|---|---|
| Phase 2 obesity results published | 2023 | Complete |
| Phase 3 TRIUMPH enrollment | 2023–2025 | Largely complete |
| TRIUMPH obesity and diabetes data readouts | 2026 | Ongoing |
| Regulatory submission to the FDA | 2026–2027 | Not yet filed |
| FDA approval decision | 2027 or later | Not decided |
| US commercial launch | 2027–2028, if approved | Not available |
Filing for approval almost always happens after the full dataset from the pivotal trials is available, and review itself can take six to twelve months even with an expedited pathway. The honest takeaway is that the earliest realistic path to a US prescription runs through 2027.
The most reliable retatrutide news tends to show up in Lilly's quarterly earnings calls and in ClinicalTrials.gov updates, not in social media posts claiming a launch date.
Is retatrutide available in the USA?
No. Retatrutide is not available in the USA, and there is no legal pathway to a prescription here. It has not been reviewed or approved by the US Food and Drug Administration, so no US pharmacy, telehealth service, or compounding pharmacy can legally dispense it for human use.
Anyone in the United States who wants retatrutide today has exactly one legitimate option: joining a clinical trial. Everything else is an unregulated product with no guarantee of what it actually contains.
Retatrutide in Europe, Canada, Mexico, and India
No country has approved retatrutide, so the answer is the same almost everywhere: it is not available. Approval timelines differ by region, and most regulators move more slowly than the FDA.
| Region | Availability status |
|---|---|
| United States | Not approved; Phase 3 ongoing |
| European Union | Not approved; no EMA filing yet |
| United Kingdom | Not approved |
| Canada | Not approved |
| Mexico | Not approved; no legal retail supply |
| India | Not approved |
| Colombia | Not approved |
People ask whether they can buy retatrutide in Mexico because pharmacies there sell other weight loss drugs more loosely, but retatrutide is not one of them. A vial labeled retatrutide from a foreign pharmacy is unverified and may contain nothing but filler or a different compound entirely.
European regulators typically lag behind the FDA by six to twelve months, and approvals in Canada, India, and Latin America often follow even later. Retatrutide availability outside the US will likely trail the American launch rather than lead it.
Can you buy retatrutide online right now?
Retatrutide sold online is a research chemical, not a medicine. These products are manufactured without pharmaceutical oversight, which means no guaranteed sterility, no verified dose, and no confirmed identity of the compound in the vial.
Gray-market storefronts frequently bundle unrelated compounds, which is why a search for aod 9604 and retatrutide, or for when to take aod 9604 peptide, tends to land on the same unregulated vendor pages. Buying from those sites carries real risk of infection, dosing errors, and unknown side effects, and none of it is legally protected.
What could speed up or slow down the timeline
- Strong trial data: large weight loss results with clean safety reporting can support priority review and faster filing.
- Safety signals: cardiovascular, gastrointestinal, or liver problems in the TRIUMPH program would delay submission and could end the program entirely.
- Manufacturing capacity: Lilly has been investing heavily in production, which matters for supply at launch.
- Competition: rival obesity drugs influence filing strategy and pricing, so a breakdown of cagrilintide vs retatrutide vs tirzepatide helps explain how the market may shake out.
Lilly is also developing an oral GLP-1 candidate, and questions about when will eli lilly weight loss pill be available follow the same readout-then-filing-then-approval pattern.
What to do while you wait
Several FDA-approved options already exist for weight management and type 2 diabetes, including semaglutide and tirzepatide. They are prescription-only, and a clinician can help you weigh benefits, side effects, and cost.
If you are considering retatrutide, the safest path is to talk with a healthcare professional about current alternatives and to ask whether any trial near you is recruiting. No supplement, research peptide, or imported vial is a substitute for a regulated medication, and none of this information should replace personalized medical advice.
Frequently Asked Questions
Is retatrutide available in the USA yet?
No. Retatrutide has not been approved by the FDA, so it cannot be prescribed or sold legally in the United States. The only way to receive it in the US today is by enrolling in a clinical trial.
When will retatrutide be approved?
A US approval decision is unlikely before 2027. Eli Lilly's Phase 3 TRIUMPH trials are expected to report key obesity and diabetes results in 2026, and a regulatory submission would follow that data, with review taking months after that.
Can you buy retatrutide in Mexico or Canada?
No. Neither Mexico nor Canada has approved retatrutide, so pharmacies there cannot legally stock it. Products marketed online or in foreign pharmacies as retatrutide are unregulated and may not contain the actual drug.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.